Here are the Form 4 insider transactions from Merck & Co., Inc. (MRK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRK filings page.
Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported routine equity compensation activity. He exercised 1,377 Restricted Stock Units (RSUs), converting them into the same number of Merck common shares at a reported value of $110.03 per share. To cover tax obligations, 679 common shares were disposed of through a tax-withholding transaction rather than an open-market sale. Following these transactions, Oosthuizen directly holds about 21,895.389 common shares. Footnotes state that each RSU represents a contingent right to one share of common stock and that the RSUs vest in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028, highlighting that this event is part of an ongoing vesting schedule.
Merck & Co., Inc. director Christine E. Seidman received a grant of 67.5451 phantom stock units on March 31, 2026. These units track Merck common stock on a 1-for-1 basis at a reference value of $120.29 per unit.
The phantom stock units are to be settled 100% in cash upon her termination of service under the Plan for Deferred Payment of Directors' Compensation. Following this grant, her phantom stock holdings total 19,238.3277 units, and she also holds 100 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
GLOCER THOMAS H reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Thomas H. Glocer received a grant of 405.2706 phantom stock units on March 31, 2026, credited at $120.29 per unit on a 1-for-1 basis with common stock. These phantom units are payable 100% in cash after his board service ends under the deferred compensation plan. He also reports direct ownership of 5,100 shares of Merck common stock, including shares accumulated through dividend reinvestment.
Merck & Co., Inc. director Mary Ellen Coe received a grant of 249.3973 phantom stock units on common stock equivalents. The units were awarded at a reference price of $120.2900 per unit and are structured on a 1-for-1 basis with Merck common stock.
The phantom stock units are to be settled 100% in cash upon Coe’s termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After this award, her phantom stock holdings total 29,702.6519 units. A separate holding entry shows she directly owns 10 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
Merck & Co., Inc.’s Chief Marketing Officer, Chirfi Guindo, reported an open-market sale of company stock. On 02/12/2026, he sold 10,000 shares of Merck common stock at a weighted average price of $121.4562 per share, through multiple trades in a narrow price range.
After this transaction, Guindo directly beneficially owned 60,615.127 shares of Merck common stock. The filing notes that detailed trade-by-trade pricing within the $121.4400 to $121.5150 range is available upon request.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported an open-market sale of common stock. On February 10, 2026, he sold 10,235 shares of Merck common stock at a weighted average price of $117.5226 per share.
After this transaction, Li beneficially owned 92,035.05 shares of Merck common stock in direct form. The sale was executed through multiple trades within a price range of $117.5200 to $117.5550, with the reported price reflecting the weighted average across those trades.
Merck & Co., Inc. Chief Marketing Officer Chirfi Guindo reported selling 10,000 shares of Merck common stock on 02/09/2026. The sale was executed at a weighted average price of $118.4101 per share, with individual trades ranging from $118.4000 to $118.4502. After this transaction, Guindo beneficially owns 70,615.127 shares of Merck common stock directly.
Merck & Co., Inc. executive vice president and general counsel Jennifer Zachary reported option exercises and related share sales in company stock. On 02/09/2026, she exercised three stock option grants covering 25,946, 56,792 and 38,835 shares of common stock, which had previously vested in scheduled installments. On the same date, she sold corresponding amounts of Merck common shares at a weighted average price of $119.1522 per share, with individual sale prices ranging from $118.9600 to $119.5100. Following these transactions, she directly held 68,915.671 shares of Merck common stock.
Merck & Co., Inc. executive David Michael Williams reported an option exercise and share sale. On February 6, 2026, he exercised 5,000 stock options at $77.62 per share, receiving 5,000 shares of common stock, and then sold 5,000 common shares at $121.905 per share. Following these transactions, he directly owned 30,837.743 shares of Merck common stock and held 4,600 stock options.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported exercising stock options and selling shares of common stock. On 02/04/2026, he exercised an option for 4,000 shares of Merck common stock at an exercise price of $62.07 per share.
On the same date, Smart reported selling 4,000 Merck common shares at $119.675 per share, followed by an additional sale of 2,400 shares at the same price. After these transactions, he directly owned 8,204.816 shares of Merck common stock. The option originally vested in three equal annual installments beginning in 2018.
Merck & Co., Inc. President, U.S. Market, Johannes Jacobus Oosthuizen reported selling 15,000 shares of Merck common stock on February 6, 2026 at a weighted average price of $121.8661 per share. The sale occurred in multiple trades between $121.8200 and $121.9500. After this transaction, he directly beneficially owned 21,197.389 Merck shares.
Merck & Co., Inc. executive vice president and CFO Caroline Litchfield reported an option exercise and share sale. On February 4, 2026, she exercised 41,997 stock options at an exercise price of $53.06 per share, receiving the same number of common shares.
On the same date, she sold 41,997 Merck common shares at a weighted average price of $119.6112 per share, in multiple trades between $119.5400 and $119.7800. After these transactions, she directly owned 90,192.194 Merck common shares.
Merck & Co., Inc. executive Dean Y. Li reported an option exercise and share sale. On 02/04/2026 he exercised a stock option for 15,087 shares of common stock at an exercise price of $56.04 per share, increasing his direct holdings to 117,357.05 shares.
That same day, he sold 15,087 shares of Merck common stock at a weighted average price of $118.7661 per share, in multiple trades between $118.7200 and $118.8300. After the sale, he directly owned 102,270.05 Merck shares.
Merck & Co., Inc. executive stock sale: Chief Marketing Officer Chirfi Guindo sold 20,000 shares of Merck common stock on February 5, 2026 in an open-market transaction. The weighted average sale price was $121.8838 per share, with individual trades ranging from $121.84 to $121.97.
After this sale, Guindo still directly owns 80,615.127 Merck shares, so he remains a significant internal shareholder. The filing notes that detailed trade prices within the reported range are available on request from Merck, its security holders, or the SEC staff.
Merck & Co., Inc. executive Richard R. DeLuca, Jr. reported a sale of company stock. On 02/06/2026, he sold 37,685 shares of Merck common stock at a weighted average price of $120.9241 per share, in multiple trades between $120.7350 and $121.3054.
After this transaction, DeLuca directly beneficially owned 160,173.834 Merck shares. The filing lists him as Executive Vice President and President, Merck Animal Health, and shows no derivative securities activity for this date.
Merck & Co., Inc. Chairman, CEO and President Robert M. Davis reported two open-market sales of Merck common stock on February 4, 2026. He sold 14,972 shares at a weighted average price of $117.3796 per share and 32,462 shares at a weighted average price of $118.3513 per share, with both transactions coded as sales. After these trades, he directly beneficially owned 443,601.757 shares of Merck common stock.
Merck & Co., Inc. executive Jennifer Zachary, EVP and General Counsel, reported an acquisition of 11,583 shares of common stock on January 26, 2026. The shares were distributed as net after-tax stock upon satisfying performance criteria for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over a three-year performance period ending December 31, 2025.
Following this transaction, Zachary directly holds 68,915.671 shares of Merck common stock.
Merck & Co., Inc. executive vice president and Chief Information & Digital Officer David Michael Williams received 6,112 shares of common stock on January 26, 2026 as an acquired award. These shares were distributed as net after‑tax stock upon meeting performance criteria for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and included dividends accrued over the three-year performance period ending December 31, 2025. Following this transaction, Williams beneficially owns 30,837.743 shares of Merck common stock, held directly and including shares acquired through dividend reinvestment.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported the acquisition of 1,066 shares of common stock on January 26, 2026. The shares were issued upon satisfaction of performance criteria for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over the three-year performance period ending December 31, 2025. Following this distribution, Smart beneficially owns 10,604.816 Merck common shares in direct ownership, including shares previously acquired through dividend reinvestment.
Merck & Co., Inc. executive Joseph Romanelli received 5,703 shares of common stock as a performance-based award. The shares were credited on January 26, 2026 at a value of $107.40 per share, increasing his directly held stake to 28,739.343 shares.
The award represents net after-tax shares distributed upon meeting performance criteria for performance share units granted on March 31, 2023. These performance shares paid out at 94% of the target award and include dividend equivalents accrued over the three-year performance period ending December 31, 2025. His holdings also include shares accumulated through dividend reinvestment.
Merck & Co., Inc. executive Johannes Jacobus Oosthuizen, President, U.S. Market, reported an automatic acquisition of 5,026 shares of common stock on January 26, 2026 at a reference price of $107.40 per share. These shares were distributed as net, after-tax stock following satisfaction of performance criteria for performance share units granted on March 31, 2023, which paid out at 94% of target and included dividends accrued over the three-year performance period ending December 31, 2025.
Following this award, Oosthuizen beneficially owns 36,197.389 shares of Merck common stock in direct ownership, and holdings also reflect shares acquired through dividend reinvestment transactions.
Merck & Co., Inc.’s EVP and CFO Caroline Litchfield reported receiving 15,852 shares of common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and include dividends that accrued over the three-year performance period ending December 31, 2025. Following this award, Litchfield beneficially owns 90,192.194 shares of Merck common stock directly.
Merck & Co., Inc. Executive VP & President, MRL Dean Y. Li reported an acquisition of 20,469 shares of Merck common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023, with performance paid out at 94 percent of the target award and including dividends accrued over a three-year period ending December 31, 2025.
Following this distribution, Li beneficially owned 102,270.05 Merck shares in direct form, which also include shares acquired through dividend reinvestment transactions.
Merck & Co., Inc. Chief Marketing Officer Chirfi Guindo reported receiving 9,865 shares of common stock on January 26, 2026, coded as an acquisition. The shares were valued at $107.4 per share and resulted from performance share units granted on March 31, 2023.
The award reflects performance shares paid out at 94 percent of target, including dividends accrued over a three-year performance period ending December 31, 2025. After this transaction, Guindo beneficially owns 100,615.127 Merck common shares directly, plus 56.7708 shares held indirectly through a 401(k) plan.
Merck & Co., Inc. executive Richard R. DeLuca, Jr., EVP & President of Merck Animal Health, reported receiving 12,264 shares of Merck common stock on January 26, 2026. These shares were distributed after performance criteria were met for performance share units granted on March 31, 2023.
Performance shares were paid at 94 percent of target awards and include dividends accrued over the three-year performance period ending December 31, 2025. After this award, DeLuca beneficially owned 197,858.834 shares of common stock directly and 1,312.5134 shares indirectly through the Merck U.S. Savings Plan, a 401(k) plan.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported an acquisition of common stock tied to a performance award. On January 26, 2026, he received 47,434 shares of common stock at a stated price of $107.4 per share, coded as an acquisition. The footnote explains this was a distribution of net after‑tax shares following satisfaction of performance criteria for performance share units granted on March 31, 2023, with performance shares paid out at 94% of target awards, including accrued dividends over a three‑year performance period ending December 31, 2025. After this distribution, Davis directly beneficially owns 491,035.757 common shares.
Merck & Co., Inc. executive Sanat Chattopadhyay acquired 13,880 shares of common stock on January 26, 2026. The shares were distributed after performance criteria were met for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over a three-year period ending December 31, 2025.
Following this transaction, he directly holds 13,880 Merck shares and indirectly holds additional shares through three Grantor Retained Annuity Trusts with 74,289, 57,622, and 53,417 shares respectively, over which he maintains complete investment control as sole trustee.
Merck & Co., Inc. director Christine E. Seidman reported routine changes in her equity holdings. On 12/31/2025 she disposed of 100 shares of Merck common stock. The filing also shows an acquisition of 77.1898 phantom stock units tied to Merck common stock at a reference price of $105.26 per share, bringing her total phantom stock holdings to 19,025.6686 units held directly.
According to the disclosure, each phantom stock unit is on a 1-for-1 basis with Merck common stock and will be settled 100% in cash after her termination of service, under the company’s deferred compensation plan for directors. Her holdings also include shares previously acquired through dividend reinvestment.
Merck & Co., Inc. director Thomas H. Glocer reported an equity compensation update. On 12/31/2025, he acquired 463.1389 phantom stock units, which are linked on a 1-for-1 basis to Merck common stock and are to be settled entirely in cash after his termination of service, under the company’s Plan for Deferred Payment of Directors' Compensation.
Following this transaction, he beneficially owns 107,075.6744 phantom stock units and 5,100 shares of Merck common stock directly. The holdings include shares accumulated through dividend reinvestment. Phantom stock gives economic exposure to the share price without issuing actual shares.
Merck & Co., Inc. director Mary Ellen Coe reported an acquisition of derivative securities linked to the company’s common stock. On 12/31/2025, she received 285.0086 phantom stock units, each tied on a 1-for-1 basis to Merck common shares, at a reference price of $105.26 per unit. Following this transaction, she holds 29,231.5716 phantom stock units directly.
The phantom stock units are to be settled 100% in cash upon her termination of service, according to a distribution schedule elected under Merck’s Plan for Deferred Payment of Directors’ Compensation. Her holdings also include shares acquired through dividend reinvestment, reflecting ongoing participation in Merck’s director compensation and deferral programs rather than open-market share purchases.
Merck & Co., Inc. (MRK) reported an insider transaction on Form 4. Chief Communications & Public Affairs Officer Cristal N. Downing sold 7,085 shares of Merck common stock at $87 on 11/10/2025 (transaction code S), and reported 0 shares beneficially owned following the sale.
The filing indicates direct ownership for the transaction. The document was signed by an attorney-in-fact on behalf of the reporting person.